Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Inhibitor Therapeutics ( (INTI) ) just unveiled an update.
On February 19, 2026, Inhibitor Therapeutics, Inc. entered into a securities purchase agreement with an institutional investor to raise $3 million by selling 12 million common shares at $0.25 each and issuing a warrant for up to 7 million additional shares. The financing, which had not closed as of February 24, 2026, is intended to bolster working capital and general corporate purposes, with all securities initially subject to transfer restrictions under U.S. securities laws.
The associated three-year warrant will be exercisable at $0.35 per share and could generate up to $2.45 million in additional gross proceeds if fully exercised. A lock-up agreement restricts the investor from selling or transferring the financing shares and any warrant shares for nine months after signing, or until a change in control, helping stabilize the shareholder base and limiting near-term selling pressure on the stock.
More about Inhibitor Therapeutics
Inhibitor Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics, with its operations centered on advancing drug candidates and related technologies. The company accesses capital markets to fund working capital and general corporate purposes, supporting ongoing research, development and corporate activities.
Average Trading Volume: 28,385
Technical Sentiment Signal: Buy
Current Market Cap: $10.35M
Learn more about INTI stock on TipRanks’ Stock Analysis page.